Cisplatin (4 mg/kg, i.v.) induced both early
emesis, which appears within the first 8-h period, and delayed
emesis, which appears between 8 and 48 h after its administration to pigeons.
GR205171 ([(2S-cis)-N-((2-methoxy-5(5-(trifluoromethyl)-1H-tetrazol-1-yl)-phenyl) methyl)-2-phenyl-3-piperidinamine dihydrochloride]) administered intramuscularly (1-10 mg/kg) reduced significantly the number of
emetic response to
cisplatin: this reduction was 60-81% (P < 0.05) for early
emesis and 48-64% (P < 0.05) for the delayed response. Intracerebroventricularly administered
GR205171 (30 microg/kg) also reduced the number of
emetic responses: 53% (P < 0.05) in early
emesis and 88% (P < 0.05) in the delayed response. However, the latency time to the first
emesis was not affected by
GR205171. Direct injection of
cisplatin (10 microg/kg) into the fourth ventricle produced
emesis, which was reduced by
GR205171 administered via the peripheral or central route.
Substance P-immunoreactive fibres were distributed throughout the dorsal vagal complex. These results suggest that the
antiemetic effect of
GR205171 on both
emetic responses to
cisplatin acts on a central site, and that the onset of the
emetic response may be mediated partly via GR205171-insensitive mechanisms.